Navigation Links
Abbott's SIMCOR ® ( niacin extended-release / simvastatin ) Receives FDA Approval for New Dosage Strengths
Date:7/28/2010

mixed dyslipidemia and type II hyperlipidemia.  The SIMCOR 40 mg strengths will be available in early August 2010.

Treatment guidelines endorsed by the National Cholesterol Education Program, the American College of Cardiology and the American Heart Association have called for more aggressive management of lipids, including a lower LDL goal for some patients, as well as more aggressive management of HDL and triglycerides.

Important Safety Information About SIMCOR

SIMCOR should not be used by people with liver problems, stomach ulcers, or serious bleeding problems; in women who are pregnant, may become pregnant, or nursing.  Unexplained muscle pain, tenderness, or weakness may be a sign of a serious but rare muscle disorder, from which rare cases of death have occurred.  This risk of these muscle side effects is increased when SIMCOR is taken with certain types of medicines.  SIMCOR is associated with increases in liver enzymes as measured by blood tests.  Blood tests should be performed before and during treatment with SIMCOR to check for liver problems.  SIMCOR should be used with caution by patients who consume large amounts of alcohol.  SIMCOR may cause an increase in blood sugar levels which should be monitored closely in patients with diabetes.  

Flushing (warmth, redness, itching, and/or tingling of the skin) is a common side effect that may subside after several weeks of consistent use.  Other common side effects include headache, itching, nausea, back pain, and diarrhea.  

More information about SIMCOR, including full prescribing information, is available on the Web site

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
2. Slo-Niacin(R) Offers More Than 20 Years of Heart Health Support
3. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
4. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
5. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
6. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
7. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
8. New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
9. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
10. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
11. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 According to a ... (Breast, Lung, Prostate) Type (Protein & Genetic Biomarkers) Profiling ... Prognostic) & Geography - Global Forecast to 2020", published ... reach around 17,689.0 Million USD by 2020 at a ... to 2020. Browse 191 Tables and ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... subset analyses of progression-free survival in,the SPARC ... in,relative risk of disease progression for patients ... as well as presence or absence of ... Pharmion,Corporation and GPC Biotech AG today announced ...
... Results in Improved Long-term [Five-years],Overall Survival for ... 2007 /PRNewswire-FirstCall/ -- FOLFOX4, an,Eloxatin(R)-based chemotherapy regimen, ... survival (OS) and,time to disease progression (TTP) ... in patients with metastatic (advanced) colorectal cancer.,Importantly, ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 2Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 3Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 4
(Date:8/28/2015)... ... ... An online provider of CPAP machines, masks, supplies, and accessories, My Cpap ... by offering shipping at no cost to you, directly to your door on all ... My Cpap Store is located in Las Vegas, Nevada. , Sleep apnea is a ...
(Date:8/28/2015)... ... 2015 , ... With the goal of furthering music education programs in schools, ... Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by ... in the underfunded school districts of Mendon and its neighboring town of Quincy, IL. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The ... the renowned Brain Aneurysm Foundation has added yet another accolade to its cadre of ... Emanuel. , “With the help of the medical community and the University ...
(Date:8/28/2015)... , ... August 28, 2015 , ... “ Frequentz ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers how this software allows businesses to track product movement from beginning ...
(Date:8/28/2015)... ... 2015 , ... The Nashville Business Journal recently announced its ... Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one of ... Awards will recognize Nashville military veterans who, through their professional and personal efforts, ...
Breaking Medicine News(10 mins):Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2
... the safety of a potential vaccine against mesothelioma, a ... which infuses uses a patient,s own dendritic cells (DC) ... induce a T-cell response against mesothelioma tumors. "[This] ... patients with mesothelioma," wrote Joachim G Aerts M.D., Ph.D., ...
... A new iPhone app designed ... gone on sale on the App Store , ... (PRWeb UK) March 3, 2010 -- The Quickka Calories PRO iPhone app is aimed at ... items that they eat., , ,In what is being called a perfect union between technology and ...
... ... ... ... ...
... ... , ... , , , ... HOUSTON , March ...
... University of Texas M. D. Anderson Cancer Center, researchers found ... bladder cancer, is a cost-effective method of detecting tumors. ... well as the number of false positives that may result ... The study was presented today in advance of the American ...
... University of Washington,s Dr. H. Hunter Handsfield, a long-time ... the nation,s highest honor in the STD field during ... STD Prevention Conference in Atlanta, March 8-11. Handsfield ... named for Dr. Thomas Parran, Jr., U.S. Surgeon General ...
Cached Medicine News:Health News:Possible vaccine for mesothelioma proven safe 2Health News:Barcode Joins the Battle of the Bulge in New iPhone App 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 3Health News:Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants 2Health News:Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study finds 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 3Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 4
... For use as a quality assurance ... human immunodeficiency virus type 1 (anti-HIV-1), ... I (anti-HTLV-I), antibody to hepatitis C ... core antigen (anti-HBc), antibody to cytomegalovirus ...
... the first,diagnostic hepatitis assay approved by the,U.S. ... in a random access format on,the VITROS ... run a hepatitis test at any time, ... for,the qualitative in vitro determination of total,antibody ...
... This SIGNET anti-PSA antibody gives ... all cases of benign hyperplasia. In ... intense staining and 34% give definite ... only a minority of cells; this ...
... kit is based on sequential binding of ... one (specific for the *-chain of HCG) ... (specific for the *-chain of HCG) conjugated ... washing step, chromogenic substrate is added and ...
Medicine Products: